MXPA05000880A - Probioticos para funciones neuromusculares del intestino. - Google Patents

Probioticos para funciones neuromusculares del intestino.

Info

Publication number
MXPA05000880A
MXPA05000880A MXPA05000880A MXPA05000880A MXPA05000880A MX PA05000880 A MXPA05000880 A MX PA05000880A MX PA05000880 A MXPA05000880 A MX PA05000880A MX PA05000880 A MXPA05000880 A MX PA05000880A MX PA05000880 A MXPA05000880 A MX PA05000880A
Authority
MX
Mexico
Prior art keywords
gut
probiotics
abnormalities
proboscis
prevention
Prior art date
Application number
MXPA05000880A
Other languages
English (en)
Inventor
Stephen Michael Collins
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29797269&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05000880(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MXPA05000880A publication Critical patent/MXPA05000880A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se relaciona con la utilizacion de probioticos en composiciones nutricionales o medicamentos para la prevencion o tratamiento de anormalidades intestino-neuromusculares. Tales anormalidades son, por ejemplo, asociadas con colicos en bebes, dolor intestinal o malestar intestinal en general. En particular, la invencion se relaciona con la prevencion o tratamiento de anormalidades intestino-neuromusculares posteriores a una infeccion. Los probioticos pueden ser administrados vivos o muertos, y tambien pueden utilizarse directamente en un medio de fermentacion sobrenadante, para lograr los efectos beneficiosos que aqui se reportan.
MXPA05000880A 2002-07-23 2003-07-23 Probioticos para funciones neuromusculares del intestino. MXPA05000880A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078064A EP1384483A1 (en) 2002-07-23 2002-07-23 Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
PCT/EP2003/008076 WO2004009103A1 (en) 2002-07-23 2003-07-23 Probiotics for gut neuromuscular functions

Publications (1)

Publication Number Publication Date
MXPA05000880A true MXPA05000880A (es) 2006-01-24

Family

ID=29797269

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000880A MXPA05000880A (es) 2002-07-23 2003-07-23 Probioticos para funciones neuromusculares del intestino.

Country Status (18)

Country Link
US (1) US8021656B2 (es)
EP (2) EP1384483A1 (es)
JP (1) JP2005538087A (es)
KR (1) KR20050025978A (es)
CN (1) CN100480370C (es)
AT (1) ATE534396T1 (es)
AU (1) AU2003250149B2 (es)
BR (1) BR0313185A (es)
CA (1) CA2493255A1 (es)
ES (1) ES2376664T3 (es)
IL (1) IL166442A0 (es)
MX (1) MXPA05000880A (es)
NO (1) NO20050896L (es)
NZ (1) NZ538335A (es)
PT (1) PT1531841E (es)
RU (2) RU2346036C2 (es)
WO (1) WO2004009103A1 (es)
ZA (1) ZA200501559B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2512812A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
MY143693A (en) 2004-03-24 2011-06-30 Nestec Sa Shelf stable product wih living micro-organisms
CA2598961C (en) * 2005-02-28 2016-09-13 N.V. Nutricia Nutritional composition with probiotics
BRPI0613802A2 (pt) * 2005-07-20 2011-02-15 Unilever Nv método de preparação de um produto comestìvel e produto comestìvel
WO2007038466A2 (en) * 2005-09-27 2007-04-05 Cobb & Company Treatment of bipolar disorder utilizing anti-fungal compositions
AU2007216461B2 (en) * 2006-02-15 2012-08-30 Société des Produits Nestlé S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
ES2553636T3 (es) * 2006-03-07 2015-12-10 Nestec S.A. Mezcla simbiótica
CA2655665A1 (en) * 2006-05-26 2007-12-06 Nestec S.A. Methods of use and nutritional compositions of touchi extract
KR101521123B1 (ko) * 2006-05-28 2015-05-19 시플라 메드프로 리서치 앤드 디벨롭먼트 (피티와이) 엘티디 프로바이오틱 스트레인 및 그로부터 유도된 항균 펩티드
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
EP2209527B1 (en) * 2007-10-11 2012-12-05 DuPont Nutrition Biosciences ApS Pharmaceutical compositions comprising L. acidophilus and Bifidobacterium lactis for use in the treatment of functional bowel disorder
ES2395838T3 (es) * 2007-12-21 2013-02-15 Compagnie Gervais Danone Método para disminuir el contorno abdominal administrando una bacteria del tipo Bifidobacterium
CN102099808A (zh) * 2008-05-15 2011-06-15 尤多克斯有限责任公司 利用针对性的益生菌来改善人体健康的方法和***
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
EP2216034A1 (en) * 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus helveticus CNCM I-4095 and weight control
WO2010103132A1 (es) * 2009-03-10 2010-09-16 Hero España, S.A. Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna
ES2559008T3 (es) * 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
AU2011209407B2 (en) * 2010-01-28 2014-02-27 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
RS55608B1 (sr) * 2010-08-10 2017-06-30 Chr Hansen As Nematocidalna kompozicija koja sadrži bacillus subtilis i bacillus licheniformis
EP2455094A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
JP5681533B2 (ja) * 2011-03-14 2015-03-11 ビオフェルミン製薬株式会社 消化管痛の予防又は軽減剤
US9579353B2 (en) * 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
US20130045185A1 (en) * 2011-08-18 2013-02-21 Dupont Nutrition Biosciences Aps Strains and methods useful for mycotoxins
EP2609813A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of the enteric nervous system
US20130251829A1 (en) 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
UA118339C2 (uk) * 2012-09-03 2019-01-10 Біогайа Аб Бактеріальний штам lactobacillus gasseri для лікування порушення моторики кишечнику (варіанти)
AU2013318513A1 (en) * 2012-09-20 2015-04-09 Prothera Inc. Probiotic compositions and methods for the treatment of obesity and obesity-related conditions
EP2912163A1 (en) * 2012-10-25 2015-09-02 Compagnie Gervais Danone Streptococcus thermophilus strains for treating helicobacter pylori infection
WO2014096901A1 (en) * 2012-12-18 2014-06-26 Compagnie Gervais Danone Strain of bifidobacterium animalis ssp. animalis
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
PL3016527T3 (pl) 2013-06-03 2019-02-28 Proprev Ab Leczenie otyłości, zespołu metabolicznego, cukrzycy typu 2, chorób sercowo-naczyniowych, otępienia, choroby alzheimera i zapalnej choroby jelit poprzez zastosowanie co najmniej jednego szczepu bakteryjnego prevotella
CA3176938A1 (en) * 2013-08-09 2015-02-12 Ab-Biotics, S.A. Probiotic for infantile excessive crying
CN103497988B (zh) * 2013-09-23 2014-10-29 广州康代生物科技有限公司 一种安全高效乳酸菌产品的发酵生产方法
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
RU2608871C1 (ru) * 2015-11-06 2017-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" Штамм бактерий Lactobacillus paracasei 1, используемый для приготовления пробиотического препарата
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
CN105767507B (zh) * 2016-03-30 2020-12-01 遂平广源饲料科技有限公司 一种饲料用微生态制剂、无抗饲料及其制备方法
KR101765559B1 (ko) 2016-09-27 2017-08-07 이대희 노루궁뎅이버섯을 포함하는 프로바이오틱스 조성물
KR20210141920A (ko) * 2018-12-21 2021-11-23 킴벌리-클라크 월드와이드, 인크. 요실금, 과민성 방광, 또는 월경 경련을 예방 또는 치료하기 위한 조성물 및 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
WO1999017788A1 (en) 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
EP1034787A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
EP1034788A1 (en) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
IL145080A0 (en) * 1999-03-11 2002-06-30 Nestle Sa Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses
TR200200301T2 (tr) * 1999-08-05 2004-12-21 Societe Des Produits Nestle S.A. Patojenik bakterilerin sebep olduğu ishali ölemeye elverişli bifidobakteriler
EP1251747B1 (en) * 2000-01-18 2012-01-25 Société des Produits Nestlé S.A. Pet food composition for treating helicobacter species in pets
EP1276488B1 (en) * 2000-03-24 2006-12-20 Societe Des Produits Nestle S.A. Use of lactic acid bacterium for the prevention of peritonitis
WO2001097821A1 (en) * 2000-06-19 2001-12-27 Mucoprotec Pty Ltd Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
IT1320772B1 (it) 2000-11-02 2003-12-10 Proge Farm Srl Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale
CA2437931C (en) * 2001-02-19 2011-11-01 Societe Des Produits Nestle S.A. Consumable product containing probiotics
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Also Published As

Publication number Publication date
JP2005538087A (ja) 2005-12-15
RU2490325C2 (ru) 2013-08-20
ATE534396T1 (de) 2011-12-15
AU2003250149A1 (en) 2004-02-09
PT1531841E (pt) 2012-02-01
EP1531841A1 (en) 2005-05-25
RU2005104950A (ru) 2005-12-10
EP1384483A1 (en) 2004-01-28
WO2004009103A1 (en) 2004-01-29
BR0313185A (pt) 2005-06-21
CA2493255A1 (en) 2004-01-29
EP1531841B1 (en) 2011-11-23
RU2346036C2 (ru) 2009-02-10
NZ538335A (en) 2007-04-27
IL166442A0 (en) 2006-01-15
CN100480370C (zh) 2009-04-22
ZA200501559B (en) 2006-05-31
CN1678329A (zh) 2005-10-05
KR20050025978A (ko) 2005-03-14
US8021656B2 (en) 2011-09-20
US20070128178A1 (en) 2007-06-07
NO20050896L (no) 2005-04-18
RU2008132327A (ru) 2010-02-10
AU2003250149B2 (en) 2009-01-22
ES2376664T3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
MXPA05000880A (es) Probioticos para funciones neuromusculares del intestino.
NZ599302A (en) Preventing diseases in infants delivered via caesarean section
IL153989A (en) Nutritional composition comprising mixture of functional carbohydrates
HK1094455A1 (en) Use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
GB0001309D0 (en) Valve arrangement
WO2002047703A3 (en) Immune system stimulation
HUP0102489A2 (hu) Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
EP2497501A3 (en) Radionuclides for medical use
TNSN08279A1 (en) Bayer healthcare ag
HK1085927A1 (en) The use of lupin conglutin for the preparation of a medicament, food supplements or foods for the treatment of type ii diabetes
MXPA04005346A (es) Uso de microorganismos para una distribucion dirigida de sustancias a partes especificas del intestino.
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
IL159770A0 (en) Calcium salts with cytotoxic activity
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
GB0114672D0 (en) Pharmaceutical formulations and methods of medical treatment
SI1853308T1 (sl) Farmacevtski pripravek za zdravljenje rib ki se ga lahko administrira oralno postopek priprave navedenega pripravka in uporaba le tega
UA36490A (uk) Спосіб лікування гнійно-септичних захворювань м'яких тканин
RU2002127274A (ru) Применение препарата ветом-7048 впервые в качестве лекарственного препарата при лечении атрофии мозга, гидроцефалии мозга
UA34283A (uk) Спосіб діагностики порушень імунологічного статусу у людини та тварин
WO2002028430A3 (en) Treatment of juvenile rheumatioid arthritis by oral administration of pooled human immunoglobulin and an antacid
UA34333A (uk) Спосіб лікування тяжких форм флюорозу зубів
HUP0301647A2 (hu) Fibrátok alkalmazása kongesztív szívelégtelenség kezelésére használható gyógyszerkészítmény előállítására
ES2199687A1 (es) Utilizacion de la beta-ciclodextrina en la preparacion de medicamentos para el tratamiento de las enfermedades humanas o animales causadas por parasitos pertenecientes al genero cryptosporidium.

Legal Events

Date Code Title Description
FG Grant or registration